HLHamin Lee

Hamin Lee

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hamin Lee has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Ali Shalash

    Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    2 shared publications
  • Alina Jama

    Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, London, UK

    2 shared publications
  • Asmaa Helmy

    Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    2 shared publications
  • Doaa M. Mahmoud

    Department of Neurology and Psychiatry, Faculty of Medicine, Assiut University, Assiut, Egypt

    2 shared publications
  • Eman Hamid

    Department of Neurology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

    2 shared publications
  • Gaafar Ragab

    Department of Internal Medicine, Rheumatology and Clinical Immunology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt

    2 shared publications

Latest Publications

  • Open Access

    The p.Gly2019Ser is a common LRRK2 pathogenic variant among Egyptians with familial and sporadic Parkinson’s disease

    by Martina B. William, Sharifa Hamed, Ali Shalash, Eman M. Khedr, Mohamed H. Yousef, Shaimaa El-Jaafary, Gharib Fawi, Asmaa Helmy, Eman Hamid, Mohamed Essam, et al.

    The impact of LRRK2 variants on the risk of Parkinson’s disease in Egyptians remains unknown. We examined 1210 Egyptians (611 PD patients and 599 controls) from 16 governorates across Egypt for 12 LRRK2 pathogenic variants. The p.Gly2019Ser was the only variant detected, with a prevalence of 4.1% in sporadic cases, 6.5% in familial cases, and 0.68% in controls. Among p.Gly2019Ser carriers, all were heterozygous bar one homozygous patient, and all shared the common haplotype 1. Demographics and UPDRS scores did not differ between carriers and non-carriers, with most patients being males and developed PD in their fifties. Young and Early-onset PD prevalence was 37.5% in carriers and 33% in non-carriers. Familial cases were 16.6% in carriers and 11.5% in non-carriers. This study affirms that like other Mediterranean populations, Egyptians with PD have a higher prevalence of the p.Gly2019Ser variant compared to the global average. LRRK2 inhibitors could be promising therapeutic options for further exploration in this population.


  • Open Access

    The p.Gly2019Ser is the commonest pathogenic mutation in the LRRK2 gene among Egyptians with familial and sporadic Parkinson's disease

    by Mohamed Salama, Martina William, Sharifa Hamed, Ali Shalash, Eman Khedr, Mohamed Yousef, Shaimaa El-Jaafary, Gharib Fawi, Asmaa Helmy, Eman Hamid, et al.

    The impact of LRRK2 variants on the risk of Parkinson's disease (PD) in Egyptians remains unknown. We examined 1,210 Egyptians (611 PD patients and 599 controls) for 12 LRRK2 mutations. The p.Gly2019Ser was the only variant detected across Egypt, with a prevalence of 4.1% in sporadic cases, 6.5% in familial cases, and 0.68% in controls. Among p.Gly2019Ser carriers, all were heterozygous bar one homozygous patient, and all shared the common haplotype 1. Demographics and UPDRS scores did not differ between carriers and non-carriers, with most patients being males and developed PD in their fifties. Early-onset PD prevalence was 33% in carriers and 25% in non-carriers. Familial cases were 16% in carriers and 11% in non-carriers. This study affirms that like other North Africans and Mediterranean populations, Egyptians with PD have a notably high prevalence of the p.Gly2019Ser. LRRK2 inhibitors could be promising therapeutic options for further exploration in this population.